Autopsy report · NCT01214291

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

“cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

GTx

Sponsor type

Industry

Conditions

Risk of Bone Fracture Occurrences

Interventions

Toremifene

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
  “While the clinical need for and the scientific merit remain valid, this regulated drug trial was not feasible logistically due to limited funds.” (71% match in meaning)
• Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
  “Feasibility of the clinical trial could not be confirmed at the different sites.” (65% match in meaning)
• A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
  “The trial was stopped early due to insufficient study drug supply and study funding constraints” (63% match in meaning)
• Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss
  “Testing required by FDA for IND approval was too expensive to move forward with conduct of the study.” (62% match in meaning)
• Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment
  “patients insurance would not cover the cost of the study procedures” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.